Arcus Biosciences (RCUS) Stock: Buy, Sell, or Hold?
RCUS - Arcus Biosciences, Inc.
$24.44
-0.79 (-3.13%)
▼
5d:
-2.12%
30d:
-18.12%
90d:
-18.48%
HOLD
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Oct 27, 2026
23d
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Sep 29, 2026 at $25.83 · last confirmed Sep 29, 2026
Strength: 4.6/10
Get Alerted When RCUS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: RCUS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: RCUS shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: RCUS is currently trading at $24.44, which is considered slightly low relative to its 30-day fair value range of $25.12 to $29.95.
Technical Outlook: Technically, RCUS is in a uptrend. The price is currently testing key support at $24.09. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.1% recently.
Market Sentiment: RCUS scores 70/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $39.91 (+63.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, RCUS is in a uptrend. The price is currently testing key support at $24.09. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.1% recently.
Market Sentiment: RCUS scores 70/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $39.91 (+63.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$25.12 -
$29.95
Company Quality Score
66/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
89.5%
Protect Your Profits
Holding RCUS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (70/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.1%)
- BULLISH: Trading 63.3% below Wall St target ($39.91)
- CAUTION: Bottoming setup, but lagging the sector by 33% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$25.12 -
$29.95
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$24.09
Resistance Level
$27.90
Current Trend
Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.48
Wall Street Target
$39.91
(+63.3%)
Revenue Growth (YoY)
-74.4%
Share & Embed Analysis
Last updated: October 03, 2026 12:24 AM ET
Data refreshes hourly during market hours. Next update: 1:24 AM
Data refreshes hourly during market hours. Next update: 1:24 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RCUS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$371 | 49 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 54 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$199 | 49 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 63 BUY |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$310 | 66 BUY |
Advanced RCUS Option Strategies
Professional options setups generated by AI based on today's RCUS price and gamma walls.
